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Chemotherapy-mediated p53-dependent DNA damage
response in clear cell renal cell carcinoma: role of the
mTORC1/2 and hypoxia-inducible factor pathways
J Selvarajah1, K Nathawat1, A Moumen1,3, M Ashcroft2 and VA Carroll*,1
The DNA-damaging agent camptothecin (CPT) and its analogs demonstrate clinical utility for the treatment of advanced solid
tumors, and CPT-based nanopharmaceuticals are currently in clinical trials for advanced kidney cancer; however, little is known
regarding the effects of CPT on hypoxia-inducible factor-2a (HIF-2a) accumulation and activity in clear cell renal cell carcinoma
(ccRCC). Here we assessed the effects of CPT on the HIF/p53 pathway. CPT demonstrated striking inhibition of both HIF-1a and
HIF-2a accumulation in von Hippel–Lindau (VHL)-defective ccRCC cells, but surprisingly failed to inhibit protein levels of
HIF-2a-dependent target genes (VEGF, PAI-1, ET-1, cyclin D1). Instead, CPT induced DNA damage-dependent apoptosis that was
augmented in the presence of pVHL. Further analysis revealed CPT regulated endothelin-1 (ET-1) in a p53-dependent manner:
CPT increased ET-1 mRNA abundance in VHL-defective ccRCC cell lines that was significantly augmented in their
VHL-expressing counterparts that displayed increased phosphorylation and accumulation of p53; p53 siRNA suppressed
CPT-induced increase in ET-1 mRNA, as did an inhibitor of ataxia telangiectasia mutated (ATM) signaling, suggesting a role for
ATM-dependent phosphorylation of p53 in the induction of ET-1. Finally, we demonstrate that p53 phosphorylation and
accumulation is partially dependent on mTOR activity in ccRCC. Consistent with this result, pharmacological inhibition of
mTORC1/2 kinase inhibited CPT-mediated ET-1 upregulation, and p53-dependent responses in ccRCC. Collectively, these data
provide mechanistic insight into the action of CPT in ccRCC, identify ET-1 as a p53-regulated gene and demonstrate a
requirement of mTOR for p53-mediated responses in this tumor type.
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Clear cell renal cell carcinoma (ccRCC) is the most
predominant type of sporadic kidney cancer, with B25% of
patients presenting with advanced disease. Inactivating
mutations in the von Hippel–Lindau (VHL) tumor-suppressor
gene account for the majority of sporadic clear cell cancers.1
Loss of VHL function leads to accumulation of the a-subunits
of hypoxia-inducible factor (HIF) transcription factors (HIF-1a
and HIF-2a) that dimerize with HIF-1b and transactivate HIF
target genes such as vascular endothelial growth factor
(VEGF). Current therapies for treating metastatic ccRCC
include receptor tyrosine kinase and multikinase inhibitors
directed to VEGF and platelet-derived growth factor (PDGF)
pathways as well as inhibitors of mammalian target of
rapamycin (mTOR).2,3 Despite antiangiogenic therapies
having significantly increased progression-free survival in
ccRCC, overall patient survival is still low as tumors eventually
acquire resistance to these modalities.4 Therefore, combina-
tion strategies with antiangiogenics and second-generation
mTOR-targeted drugs such as the dual mTOR/PI3Kinase and
mTORC1/mTORC2 kinase inhibitors are currently being
investigated for improved therapeutic outcome for metastatic
ccRCC and other malignancies.5
The HIF-a subunits have emerged in recent years as
potential therapeutic targets in ccRCC. HIF-1a and HIF-2a
play a central, if complex, role in the development ccRCC.
Several lines of evidence demonstrate that HIF-2a is the
primary oncogenic driver in ccRCC.6–8 In addition, HIF-2a
predominantly regulates angiogenic genes such as VEGF in
this tumor type.9–11 In contrast, recent evidence suggests that
HIF-1a acts as a tumor suppressor in ccRCC.10,12 ccRCC is
also highly resistant to chemotherapy and radiotherapy and
some studies have shown that this resistance can be
circumvented by inhibition of HIF-2a.13,14 For example,
previous work in pVHL-defective RCC cell lines that express
constitutive HIF-2a has shown that ablation of HIF-2a, either
with siRNA or by reintroduction of VHL, increases
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phosphorylation and accumulation of p53.13,14 Concordantly,
HIF-2a inhibition restored sensitivity to radiation and
chemotherapy, suggesting that inhibitors of HIF-2a would be
beneficial in combination with radiotherapy, chemotherapeutics
or agents that restore p53 pathway activity. Collectively, these
data have significant implications for targeting the HIF
pathway directly as it still remains unclear whether inhibition
of HIF-1a or HIF-2a alone or in combination would be
beneficial for kidney cancer.
Camptothecin (CPT) and its analogs, topotecan and
irinotecan, are topoisomerase I inhibitors that prevent
topoisomerase I-mediated unwinding and DNA repair, leading
to accumulation of DNA double-stranded breaks and cell
death.15 These agents are also potent inhibitors of HIF-1a and
have been studied extensively for HIF-1a-targeted therapy.16–21
CPT-based nanopharmaceuticals are currently in clinical
trials for advanced kidney cancer; however, to our knowledge,
no reports exist as to the effects of CPT on HIF-2a function in
ccRCC. Therefore, in this study we investigated the effects of
CPT onHIF-2a expression and activity together with its effects
on p53 accumulation and p53-dependent responses in
ccRCC.
Results
Effect of CPT on HIF-1a, HIF-2a and HIF-a target genes in
ccRCC. Although the inhibition of HIF-1a by CPT has been
intensively studied, its effect on HIF-2a accumulation and
activity in ccRCC has not, to our knowledge, been demon-
strated. CPT dose dependently inhibited HIF-2a protein
levels in VHL-defective 786-O cells expressing constitutive
HIF-2a (Figure 1a) and HIF-1a and HIF-2a protein levels in
VHL-defective RCC4 cells that express both HIF-1a and HIF-2a
(Figure 1a). We next assessed the ability of CPT to inhibit
a number of HIF-a target genes. CPT partially inhibited
GLUT-1 and BNIP3 at 24h (Supplementary Figure 1), both of
which are predominantly regulated by the HIF-1a subunit.11,22
However, despite inhibition of HIF-2a protein, CPT failed to
have significant inhibitory activity on a number of HIF-2a
target genes that we evaluated (Figures 1a and c and
Supplementary Figure 1). Protein levels of HIF-2a-dependent
genes, cyclin D1, VEGF, plasminogen activator inhibitor-1
(PAI-1) and endothelin-1 (ET-1), were not inhibited, but were
partially elevated in RCC4 cells (Figures 1a and c). In
contrast, apigenin, which is a dietary flavonoid that has been
reported to inhibit HIF-1a- and HIF-1a-dependent VEGF,23
also inhibited HIF-2a protein levels and VEGF in 786-O and
RCC4 cells (Figure 1b). Collectively, these data suggest that
CPT is unlikely to mediate its antitumor effects through
downregulation of HIF-2a target genes such as VEGF.
Wenext assessed themechanismof action of CPT onHIF-2a
protein accumulation. Along with inhibition of constitutive
HIF-2a protein, CPT also inhibited desferrioxamine (DFX)-
induced HIF-2a protein accumulation in VHL-competent
RCC4 cells (RCC4/VHL) (Figure 2a). CPT had no effect on
HIF-2a mRNA levels (Figure 2b), suggesting that it did not
affect HIF-2amRNA synthesis or stability. As previous studies
have demonstrated that CPT inhibits HIF-1a protein synthesis,21
we incubated RCC4 cells in the presence of the 26S
proteasome inhibitor MG-132 in order to inhibit HIF-a protein
degradation. CPT markedly reduced the MG-132-induced
accumulation of HIF-1a (Figures 2c and d), consistent with
previous reports.21 Both HIF-a subunits were reduced in the
presence of the protein synthesis inhibitor, cycloheximide
(CHX), demonstrating a requirement of protein synthesis for
constitutive expression of HIF-a subunits (Figure 2d). CPT
also inhibited HIF-2a in the presence of MG-132, but to a
lesser extent than HIF-1a, suggesting that CPT also partly
inhibits HIF-2a protein synthesis.
CPT mediated p53 accumulation and apoptosis in
ccRCC. We next explored the ability of CPT to induce
p53 and p53-dependent responses in ccRCC cell lines.
Previous studies have demonstrated increased p53
accumulation in pVHL-expressing cells.13,24–26 Consistent
with these studies, we found that p53 phosphorylation and
accumulation was suppressed in VHL-defective 786-O cells
that express HIF-2a (Figure 3a) and indeed RCC4 cells that
express both HIF-1a and HIF-2a subunits (Figure 3a) as
compared with their VHL-expressing counterparts. CPT
treatment increased p53 accumulation in 786-O cells, and
to a lesser extent in RCC4 cells, that was augmented in their
VHL-expressing counterparts respectively. In addition,
cleaved poly ADP ribose polymerase (PARP) was observed
in 766-O and RCC4 cells in response to CPT that was further
increased in VHL-expressing cells (Figure 3a). We next
assessed the effects of CPT on sub-G1 content by flow
cytometry. We found that CPT increased the percentage of
cells in sub-G1 in 786-O cells that was again augmented in
786-O/VHL cells (Figure 3b and Supplementary Figure 2).
Taken together, our data indicate that CPT increases p53
accumulation and apoptosis in a VHL-dependent manner.
These results are consistent with previous studies that have
demonstrated suppression of p53 pathway activation in
VHL-defective cells.13,14,24,26
CPT increases ET-1 mRNA abundance in a p53-dependent
manner. In RCC4 cells we failed to see CPT-mediated
inhibition of VEGF, PAI-1 and ET-1, all of which are HIF-2a
target genes. However, we have previously demonstrated
that, in addition to HIF-2a, VEGF protein levels are sensitive
to mitogen-activated protein kinase signaling.27 Both
extracellular regulated kinase 1/2 phosphorylation and VEGF
are increased upon CPT treatment in RCC4 cells.27 In
addition, PAI-1 is also regulated by p53.28 We were
interested in exploring the CPT-mediated regulation of ET-1
levels further as little is known about the regulation of ET-1 in
ccRCC. ET-1 mRNA levels were determined by RT-PCR.
Consistent with previous reports we demonstrated that
constitutive ET-1 mRNA and protein were regulated in a
VHL-dependent manner, and we have previously shown that
ET-1 protein levels were partly dependent on HIF-2a
(Supplementary Figure 3).27,29 Interestingly, CPT induced
ET-1 mRNA abundance in a dose-dependent manner in
786-O cells that was significantly augmented following
reintroduction of VHL (Figures 4a and b), suggesting a role
for p53 in ET-1 induction. Similar results were observed for
the RCC4 and RCC4/VHL cells: CPT increased ET-1 mRNA
abundance in RCC4 cells that was further increased upon
reintroduction of VHL (Figure 4b). We extended our studies
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to nonrenal cells and assessed the paired isogenic cell lines
HCT116 p53þ /þ and p53 / cells. We found that CPT
increased ET-1 mRNA in HCT p53þ /þ cells, but not p53 /
cells, although the increase observed was not as significant
as that seen in ccRCC cells (Figure 4b). No effect of CPT on
ET-1 mRNA levels was observed in p53-null Saos-2 cells
(Figure 4b).
To further assess DNA-damaging agents on ET-1 mRNA
levels, we next analyzed the effects of etoposide, a
topoisomerase II inhibitor. Etoposide increased ET-1 mRNA
abundance in 786-O cells expressing VHL (Figure 4c). In
addition, nutlin-3a, which prevents the binding of MDM2 to
p53, also increased ET-1 mRNA levels (Figure 4c) as well as
p53 accumulation in both 786-O and RCC4 cells that were
augmented in their VHL-expressing counterparts (Figure 4d).
Finally, in order to confirm that the effects of CPT on ET-1
were indeed p53 dependent, we used p53 siRNA. Down-
regulation of p53 with siRNA prevented the CPT-induced
increase in ET-1 mRNA (Figure 5a) and inhibited ET-1 protein
levels in RCC4 cells (Figure 5b). Taken together, these results
demonstrate that ET-1 is induced in a p53-dependent manner
in ccRCC upon DNA damage.
p53-dependent increase in ET-1 mRNA abundance is
dependent on ATM signaling. To further explore the DNA
damage response in ccRCC cells and the effects on ET-1,
we evaluated the canonical ataxia telangiectasia mutated/
ataxia telangiectasia and Rad3-related (ATM/ATR) DNA
HIF-1α
actin
RCC4
D
M
SO
CPT, μM210.
5
0.
25
0.
12
5
0
100
200
300
400
DMSO 0.125 0.25 0.5 1 2
VE
G
F
(pg
/m
L/5
x1
05
 
ce
lls
)
CPT, μM
0
50
100
150
200
DMSO 1 5 10 25 50
Apigenin, μM
**
*
0
1000
2000
3000
4000
5000
DMSO 1 5 10 25 50
VE
G
F
(pg
/m
L/5
x1
05
 
ce
lls
)
VE
G
F
(pg
/m
L/5
x1
05
 
ce
lls
)
Apigenin, μM
**
**
HIF-2α
α-tubulin
786-O
D
M
SO
Apigenin, μM50251051
786-O
D
M
SO
HIF-2α
actin
CPT, μM210.
5
0.
25
0.
12
5
RCC4 RCC4
786-O
cyclin D1
HIF-2α
0
50
100
150
200
250
300
3 6 24
Time, h
VE
G
F 
(pg
/m
L/5
x1
05
 
ce
lls
)
DMSO
CPT
0
50
100
150
200
250
300
3 6 24
Time, h
PA
I-1
 (n
g/m
L/5
x1
05
 
ce
lls
)
DMSO
CPT
P<0.01
P<0.01
P=0.25
P=0.06
P=0.19
P=0.30
RCC4 RCC4
0
10
20
30
40
50
60
3 6 24
Time, h
ET
-1
 (p
g/m
L/5
x1
05
 
ce
lls
)
DMSO
CPT
P<0.01
P<0.01
P=0.25
RCC4
Figure 1 Effect of CPT and apigenin on HIF-1a, HIF-2a and HIF-a target genes in RCC4 and 786-O cells. (a and b) 786-O or RCC4 cells were treated with CPT or
apigenin at the concentrations indicated or vehicle control (DMSO). Panels, whole-cell lysates were assayed by western blot for HIF-1a, HIF-2a and cyclin D1 proteins. Actin
and/or tubulin were used as loading controls. Graphs, conditioned media were harvested after 24 h and secreted protein levels of VEGF were determined by ELISA and
normalized to cell number. (c) RCC4 cells were treated with 2mM CPT or DMSO vehicle control for the times indicated. Conditioned media were harvested and secreted
protein levels of VEGF, PAI-1 and ET-1 were determined by ELISA and normalized to cell number. Mean±S.E. of duplicate values of one representative experiment is shown.
*Po0.05, **Po0.01, t-test compared with control
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damage pathway. Both ATM and ATR phosphorylate p53
and can signal to CHK-1 and CHK-2 pathways in response to
DNA damage.30 Bertout et al.13 have demonstrated that p53
phosphorylation and accumulation following knockdown of
HIF-2a was prevented by an inhibitor of ATM signaling. In
addition, these authors show that radiation-induced CHK-2
phosphorylation was also inhibited by HIF-2a, demonstrating
HIF-2a-mediated suppression of the DNA damage response
pathway in ccRCC. Here we also demonstrate inhibition of
DNA damage accumulation in RCC4 cells overexpressing
both HIF-1a and HIF-2a in response to chemotherapy
(Figure 6a). CPT- and etoposide-mediated phosphorylation
of CHK-1 at Ser317 and Ser345 was suppressed in RCC4
cells as compared with VHL-competent cells. CPT-mediated
phosphorylation of the histone protein H2AX at Ser139
(gH2AX) was also suppressed in RCC4 cells as compared
with their VHL-expressing counterparts (Figure 6a). These
results are consistent with a phenotype that implicates HIF-a
in suppression of DNA damage response proteins in ccRCC.
We next investigated the effects of ATR/ATM signaling on
p53-mediated regulation of ET-1 and found that inhibition of
ATR by siRNA had no effect on CPT-induced ET-1 mRNA
levels (Figure 6b), whereas an inhibitor to ATM partially
attenuated CPT-mediated ET-1 induction in both 786-O/VHL
and RCC4/VHL cell lines and p53 phosphorylation (Figures
6c and d), suggesting that ATM signaling was in part
responsible for p53-induced increase in ET-1 mRNA.
Attenuation of mTORC1/2 signaling suppresses
p53-dependent DNA damage responses in ccRCC.
Inhibitors of mTOR have clinical utility for metastatic ccRCC.
The mTOR kinase acts downstream of phosphoinositide
3-kinase (PI3K/Akt) signaling and exists in two multiprotein
complexes: mTORC1 and mTORC2. Recent data suggest
that the mTORC2 pathway is important for HIF-2a
translation,31,32 suggesting that dual mTORC1/2 kinase inhibitors
may be more beneficial for metastatic ccRCC than rapa-
mycin analogs. We were interested in addressing the
question as to whether suppression of HIF-2a as mediated
by pharmacological blockade of mTORC1/2 kinase activity
affected p53 levels in ccRCC. We used the ATP competitive
inhibitor of mTOR, pp244, that inhibits both mTORC1
and mTORC2 signaling. pp242 significantly inhibited the
phosphorylation of mTOR and its substrate p70S6K and,
as expected, it inhibited HIF-2a accumulation in 786-O cells
(Figure 7a) and both HIF-1a and HIF-2a in RCC4
cells, consistent with previous studies (Supplementary
Figure 4A).31,33 Rapamycin, which suppresses mTORC1
signaling, did not affect HIF-2a protein levels, confirming a
role for mTORC2 in the regulation of HIF-2a (Supplementary
Figure 4B). Interestingly, rapamycin also had little effect on
HIF-1a accumulation (Supplementary Figure 4B). Next, we
assessed the effects of pp242 on p53 levels. Treatment with
pp242 did not increase p53 phosphorylation or accumulation
as might be predicted from the downregulation of HIF-2a in
786-O cells (Figure 7a) and RCC4 cells (Supplementary
Figure 4A). This suggests that either low levels of HIF-2a are
sufficient for effective suppression of p53 or that mTOR is
required for p53 accumulation in ccRCC. In order to address
the latter, we assessed p53 levels in response to pp242.
Pharmacological inhibition of mTOR with pp242 attenuated
p53 phosphorylation and accumulation in response to CPT
(Figure 7 and Supplementary Figure 5). We confirmed that
the effects of pp242 on p53 phosphorylation were not due to
a nonspecific inhibition of ATM kinase activity as the
mTORC1/2 kinase inhibitor had no effect on phosphorylation
levels of ATM, whereas it markedly reduced CPT-mediated
p53 phosphorylation in ccRCC cell lines (Supplementary
Figure 5A). In addition, no inhibition of ATM phosphorylation
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by pp242 was observed in MCF-7 and HEK-293 cells
following DNA damage with either ultraviolet irradiation or
etoposide treatment (Supplementary Figures 5B and C).
Moreover, specific targeting of mTOR with siRNA also
markedly suppressed p53 phosphorylation in HEK-293 cells
(Supplementary Figure 5D). We next assessed the ability of
pp242 to inhibit p53-dependent responses in ccRCC;
CPT-dependent induction of PAI-1 was partially inhibited by
pp242 treatment (Figure 7c). Consistent with a role for p53 in
the regulation of ET-1, pp242 significantly attenuated
CPT-dependent increase in ET-1 mRNA abundance in
RCC4 and RCC4/VHL cells (Figure 7c) and secreted protein
levels in RCC4 cells (Figure 7d). Moreover, CPT-dependent
cell death was strikingly inhibited by pp242 in ccRCC cell
lines (Figure 8a), as was CPT-induced cleavage of caspases
3, 7 and 9 as well as PARP cleavage (Figure 8b). Taken
together, these results suggest a requirement of mTOR for
p53-mediated apoptosis in ccRCC.
Discussion
There has been a renewed interest in assessing the
DNA-damaging agent CPT for anticancer therapy in ccRCC
and other solid tumors as it possesses significant HIF-1a
inhibitory activity. Early clinical studies of CPT and its analogs,
topotecan and irinotecan, failed to show activity in clinical
trials for renal cancer as patients suffered severe toxicity that
limited their clinical utility.34,35 Recent efforts to circumvent the
toxicity observed with CPT have led to the development of
novel delivery systems such as the cyclodextrin-containing
polymer nanopharmaceutical, CRLX101, that has improved
solubility and retention profiles.36 CRLX101 is currently in
clinical trials as a single agent for a range of tumor types and
combined with Avastin for advanced kidney cancer.
As topoisomerase I inhibitors are potent inhibitors of
HIF-1a, we were interested in whether CPT also inhibited
HIF-2a, which is considered to be the more important subunit
for kidney cancer progression. Here we addressed the effects
of CPT on HIF-a expression and activity and p53-dependent
responses. CPT ablated both HIF-1a and HIF-2a but failed to
significantly inhibit HIF-2a target genes in cells that express
both HIF-a subunits. Instead, CPT increased apoptosis in
VHL-defective ccRCC cell lines that was augmented in their
VHL-expressing counterparts, confirming a role for the
VHL/HIF pathway in resistance to chemotherapeutics
consistent with previous studies.13,14,24,26 We still observed
some resistance to p53-dependent apoptosis in 786-O cells
with CPT as compared with 786-O/VHL cells despite
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concurrent inhibition of HIF-2a, suggesting that low levels of
HIF-2a are able to effectively suppress p53, or that other HIF-
independent VHL pathways are also operative.26 In this study
we did not attempt to address the mechanism by which the
VHL/HIF pathway affects p53 as this has been studied
extensively by other authors.13,14,24,26,37 Instead, we were
concerned with the downstream outcome of chemotherapy
treatment that could concurrently inhibit HIF-a and activate the
p53 pathway.
p53 regulates cellular responses to stress that include the
ability to induce cell cycle arrest, apoptosis and senescence
through activating p53-responsive genes.38 Of interest was
the increased secreted phenotype in RCC4 cells treated with
high concentrations of CPT. Previous studies have demon-
strated a senescence-associated secretory phenotype
(SASP) upon severe DNA damage accompanied with
increased p53, p21CIP1 and PAI-1 levels.39 In RCC4 cells,
CPT increased p53 accumulation and activated the p53 target
genes, p21 and cyclin D1, and increased secretion of VEGF,
PAI-1 and ET-1 that have all been associated with senes-
cence in other cell types.40–43 In addition to HIF-a regulation,
PAI-1 is also a p53 target gene and we could show that PAI-1
mRNA was increased in a p53-dependent manner on CPT
treatment. Our data suggested that ET-1 was regulated in a
similar manner to PAI-1, and indeed we could show that
increased ET-1 levels were p53 dependent upon DNA
damage, whereas constitutive ET-1 mRNA and protein levels
were primarily dependent on VHL/HIF. To determine whether
p53might regulate ET-1 transcription directly, we performed a
search of the proximal promoter, and three putative p53
DNA-binding sites were identified (Supplementary Figure 6A).
One of these, designated DNA-binding site 1 (DBS1), has
high homology with mouse and rat ET-1 genes. Interestingly,
a recent study has demonstrated ET-1 to be a transcriptional
target of p53 in epidermal keratinocytes, raising the possibility
that p53 may regulate ET-1 transcription directly.44
In the vascular system, ET-1 is a potent vasoconstrictor and
has a diverse range of physiological functions including
maintenance of vessel tone, smooth muscle cell proliferation
and promotion of angiogenesis.45 Pathophysiological levels of
ET-1 contribute to a number of cardiovascular diseases.46–48
In the kidney, it has been reported that ET-1 is a survival factor
for renal carcinoma cells that express the ET-A receptor
(ETA),
49 and a recent report suggested that patients receiving
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ET receptor antagonist therapy combined with interferon-a
had a better outcome than interferon-a alone,50 suggesting
that blockade of ET-1 signaling would be beneficial for
metastatic RCC. In this context, p53-dependent increase of
ET-1 may limit efficacy of chemotherapeutics; however, we
found little effect of ET-A receptor blockade on CPT-mediated
cell death (Supplementary Figures 6C and D). Nevertheless,
the biological significance of the p53-dependent increase of
ET-1 warrants further investigation.
The mTOR pathway is a major cancer drug target and renal
cell carcinoma is one cancer that has demonstrated clinical
success with rapalog therapy. mTOR exists in two multi-
protein functional complexes: mTOR complex 1 (mTORC1)
and mTOR complex 2 (mTORC2). Rapamycin, which binds
the FKBP-rapamycin-binding domain and not the ATP binding
pocket, predominantly inhibitsmTORC1 complex formation.51
As recent data have demonstrated that mTORC2 is important
for HIF-2a protein translation in ccRCC,31,32 we asked the
question of whether HIF-2a ablation by an mTORC1/2 kinase
inhibitor, which interacts with the ATP binding pocket of
mTOR and thus inhibits both mTORC1 and mTORC2 activity,
affected p53 status in ccRCC cells. We could show that
HIF-2a inhibition mediated by pp242 did not result in
increased p53 accumulation. Instead, mTOR was required
for p53 phosphorylation and accumulation following
CPT treatment in both 786-O and RCC4 cells and their
VHL-expressing counterparts. mTOR and p53 pathways act
in a coordinated manner to regulate cell growth, proliferation
and death depending on extracellular signals. p53 can
attenuate mTOR activity and signaling in response
to genotoxic stress by induction of p53 target genes.52,53 In
addition, in other cellular contexts, mTOR can regulate p53.54
Our results are consistent with the latter observations.
Collectively, our data suggest that CPT is unlikely to mediate
its antitumor effects by inhibition of HIF-2a target genes such as
VEGF and support current clinical efforts combining Avastin
with CPT-based nanodrugs. Importantly, we show that CPT
mediates its effects through classical DNA damage-induced
p53-dependent apoptosis. Moreover, we uncover a novel
regulation of ET-1 by p53 in ccRCC and show that
p53-dependent apoptosis is dependent on mTORC1/2 kinase
activity in this tumor type, suggesting that potential combination
therapies of chemotherapeutics with mTOR inhibitors need to
be carefully evaluated for ccRCC.
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Materials and Methods
CPT, nutlin-3a, etoposide, apigenin, desferrioxamine, cycloheximide, MG-132,
methylthiazoletetrazolium (MTT) and pp242 were all purchased from Sigma-Aldrich
(Gillingham, UK). The ATM kinase inhibitor was obtained from Calbiochem
(Millipore, Watford, UK).
Cell culture. All tumor cell lines were maintained in Dulbecco’s modified
Eagle’s medium (PAA Laboratories, Yeovil, UK) supplemented with 10% fetal
bovine serum (Sigma-Aldrich), 100 IU/ml penicillin, 100 mg/ml streptomycin and
2 mM glutamine (all purchased from Life Technologies, Paisley, UK). Matched
RCC4 renal cell carcinoma cells (RCC4 and RCC4/VHL) were gifts from
Professor Patrick Maxwell (Cambridge University, UK).55 The 786-O renal cell
carcinoma cells (786-O and 786-O/VHL) were gifts from Professor William
G. Kaelin Jr (Dana-Farber Cancer Institute, Harvard Medical School, Boston,
MA, USA). Matched human colorectal carcinoma cells (HCT-116 p53þ /þ and
HCT p53 / ) were kindly provided by Professor Galina Selivanova (Karolinska
Institute, Stockholm, Sweden). The p53-null Saos-2 cells were obtained from
American Type Culture Collection (Manassas, VA, USA).
Immunoblotting. Cell treatments were performed in DMEM media containing
10% FBS for the times and concentrations as indicated in the figure legends.
Thereafter, conditioned medium was harvested and analyzed by ELISA for PAI-1
(IMUBIND, American Diagnostica, Axis-Shield, Stockport, UK), VEGF (QuantiGlo,
R&D Systems, Abingdon, UK) and ET-1 (Quantikine, R&D Systems). In parallel,
whole-cell lysates were prepared for western blotting as described previously.56
HIF-1a monoclonal antibody was purchased from BD Biosciences (Oxford, UK).
HIF-2a polyclonal antibody (NB100-122) was purchased from Novus Biologicals
(Cambridge, UK). Monoclonal anti-actin antibody was purchased from Merck
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(Nottingham, UK) and anti-a-tubulin antibody was obtained from Sigma.
Monoclonal anti-CHK-1 antibody (sc-8408) was purchased from Santa Cruz
(Santa Cruz, CA, USA). Monoclonal anti-cyclin D1 (DCS-6) was purchased from
Thermo Fisher Scientific (Runcorn, UK). Monoclonal anti-phospho-S15-p53, and
the polyclonal-anti-phospho-antibodies S2448-mTOR, S1981-ATM, T389-p70S6K,
S317-CHK-1, S296-CHK-1, S345-CHK-1, S139-gH2AX and total p53, mTOR,
cleaved PARP and cleaved caspase 3, 7 and 9 antibodies were all obtained from
Cell Signaling (New England Biolabs, Hitchin, UK).
siRNA duplexes and transient transfections. Cells were transfected
with siRNA duplexes using HiPerfect (QIAGEN, Crawley, UK) transfection reagent
according to the manufacturer’s instructions and as described previously.9 siRNA
duplexes to HIF-1a, HIF-2a, p53 and a non-silencing control (NSC) duplex were
obtained from QIAGEN and have been described previously.9,57 ATR siRNA
(sc-29763) was purchased from Santa Cruz. AllStars negative control siRNA
duplex was purchased from QIAGEN.
Real-time quantitative PCR assays. Total RNA was extracted from cells
using the RNeasy Mini Kit (QIAGEN) and 50 ng total RNA was used for first-strand
cDNA synthesis using Sensiscript (QIAGEN) according to the manufacturer’s
instructions. Real-time qPCR was performed with GoTaq qPCR master mix
(Promega, Southampton, UK) in a Stratagene Mx3000 real time cycler
(Agilent Technologies, Stockport, UK). Primers for ET-1 were purchased from
Sigma-Aldrich and have been described previously (forward 50-TGGACATCATTT
GGGTCAACA; reverse 50-TCTCTTGGACCTAGGGCTTCC).58 Primers for PAI-1,
HIF-2a and GAPDH have been described previously.9 Expression of target gene
mRNA relative to reference gene mRNA (GAPDH) was calculated using the Relative
Expression Software Tool (REST, QIAGEN) and statistical significance determined
using the Pair Wise Fixed Reallocation Randomization Test available from http://
www.gene-quantification.com.
Flow cytometry. Flow cytometry was performed as previously described.56
Briefly, following treatment, cells were harvested and re-suspended in 70%
ethanol. Cells were washed with PBS and resuspended in 50 mg/ml propidium
iodide/RNAse A solution (Sigma-Aldrich) and analyzed with a Beckman Coulter
Cytomics FC500 flow cytometer.
MTT cell viability assay. Cell viability was determined by reduction of MTT
(Sigma-Aldrich). Briefly, cells were seeded in 96-well plates, washed with PBS
before addition of test compounds. MTT reagent (25ml) was added to wells after 24
or 48 h and incubated for a further 2 h. Thereafter, 100ml of 10% SDS was added to
wells and incubated for 24 h before measurement of absorbance at 595 nm.
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